Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Zhongjie Li(Henan University of Science and Technology), Guo‐Dong Lu(Guangxi University)
Cited by 300
Related Papers
ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
|Acta Pharmacologica Sinica|2020|161
Fatty acid activation in carcinogenesis and cancer development: Essential roles of long‑chain acyl‑CoA synthetases (Review)
|Oncology Letters|2018|154
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy
|Experimental & Molecular Medicine|2022|35